You are here

Our science / Clinical Trials / Find a Trial / NCT00141414

To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

Back to Search Print Save as PDF Bookmark Trial

NCT00141414

Last updated on May 12, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Little Rock, Arkansas, 72205 United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Partial Epilepsy
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have met the inclusion criteria for preceding double-blind study.

- Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Pregnant or considering becoming pregnant.

- Receiving any concomitant medication that could alter the effectiveness of their
medication response or seizure frequency.

NCT00141414
Pfizer
Completed
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Partial Seizures Epilepsy, Primary Generalized Tonic-Clonic Seizures Epilepsy
A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
NCT01463306
All Genders
0+
Years
Multiple Sites
Partial Epilepsies
Vision Testing in Patients With Partial Seizures Receiving Either Lyrica or Placebo
NCT00351611
All Genders
18+
Years
Multiple Sites
Partial Onset Seizures
A Safety, Efficacy, and Tolerability Trial of Pregabalin as Add-On Treatment in Pediatric Subjects <4 Years of Age With Partial Onset Seizures.
NCT02072824
All Genders
0+
Years
Multiple Sites
Partial Epilepsy
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
NCT00141414
All Genders
18+
Years
Multiple Sites
To Evaluate the Long-Term Safety of Pregabalin in Refractory Partial Epilepsy.
Pregabablin Open-Label, Follow-On Safety Trial In Patients With Refractory Partial Epilepsy.
To evaluate the long-term safety of pregabalin in refractory partial epilepsy.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Epilepsy, Partial
Drug: Pregabalin
Not Provided
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
82
October 2005
Not Provided

Inclusion Criteria:

  • Must have met the inclusion criteria for preceding double-blind study.
  • Have received double-blind study medication and wish to receive open-label pregabalin.

Exclusion Criteria:

  • Pregnant or considering becoming pregnant.
  • Receiving any concomitant medication that could alter the effectiveness of their medication response or seizure frequency.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany,   United States
 
 
NCT00141414
1008-008
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2006

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now